Employer-Paid

A big part of the solution is for employers to advocate for themselves and probe for deeper information when comparing plans.

The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it contends are ploys intended to delay generic competition, by disputing junk patent listings for 300 drugs.

Providers, insurers and regulators need to come together to ensure the safe use of these drugs, mitigate failed treatment attempts, reduce side effects and provide better insurance plans to support patients in need.

More than three-quarters of respondents said they feel more comfortable talking about family-related responsibilities with their employer than they did previously.

Nearly 80% of employers expect a moderate or significant impact from the DOL over the next year, as the presidential election looms. 

The BIOSECURE Act seeks to sever ties with some Chinese biotech players, however, these firms are heavily embedded in the U.S. pharmaceutical industry, which is already struggling with widespread drug shortages.

Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the FDA's Orange Book, was hit with an class action lawsuit, alleging that the company is using expired patents.

Employers must act upon this price information to redesign their health plans to better align hospital prices with the value of care provided, since price transparency alone will not lead to changes, according to a new RAND report.